NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

A collaborative study from the MRC Laboratory of Medical Sciences (LMS) and Imperial College London has found that the protein ACE2 may play a ...

Proteins circulating in the blood can reveal what’s happening in the body, from how we process energy to how diseases develop. Unlike genetic testing, which shows fixed risk factors from birth, ...

In patients with heart failure (HF) caused by Chagas disease, sacubitril/valsartan was superior to enalapril for the composite primary endpoint, predominantly driven by a significant reduction in ...

Panelists discuss how disease progression monitoring requires integrating multiple data points including symptoms, six-minute walk tests, biomarkers like BNP/NT-proBNP, and imaging studies, with risk ...

Please provide your email address to receive an email when new articles are posted on . Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an ...

PAH therapies improved hemodynamic parameters and reduced NT-proBNP levels in PH-ILD patients, indicating potential benefits. Precision medicine could help identify PH-ILD patients who may benefit ...

Diagnostic thresholds of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) for heart failure with preserved ejection fraction (HFpEF) in ambulatory patients with chronic dyspnearequire ...

Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a key biomarker for diagnosing heart failure, show a nearly fourfold increased risk for atrial fibrillation (AF) in at-risk ...